Bioequivalence Study of Tacrolimus in Healthy Volunteers

  • STATUS
    Recruiting
  • days left to enroll
    44
  • participants needed
    72
  • sponsor
    Food and Drug Administration (FDA)
Updated on 24 March 2021

Summary

This is an in-vivo study to investigate the bioequivalence of generic tacrolimus and its reference listed drug (RLD). The objective of this study is to investigate the bioequivalence of generic Tacrolimus and RLD in healthy male and non-pregnant, non-lactating female volunteers under fasting conditions. The outcome of this study will help further understanding about pharmacokinetic (PK) performance of tacrolimus in a healthy volunteer population and improve review standards for bioequivalence of narrow therapeutic index (NTI) drugs.

Description

This is a single-dose, randomized, open-label, fully replicate crossover, four-period, twotreatment, two-sequence, bioequivalence study to investigate the bioequivalence of generic tacrolimus and its reference listed drug (RLD).

Tacrolimus, a calcineurin inhibitor (CNI), has been widely used in solid organ and bone marrow transplants for more than two decades. Calcineurin, a calcium-dependent phosphatase, is instrumental for signal transduction for activation of T cell and B cell, which in turn cause production of autoinflammatory cytokines such as such as interleukin 2 (IL- 2), tumor necrosis factor-alpha (TNF-), and interferon-gamma (IFN-). CNIs prevents the dephosphorylation and translocation of various factors such as the nuclear factor of activated T-cells (NF-AT), and nuclear factor kappa-light-chain enhancer of activated B-cells (NF-B), thereby inhibiting the signal transduction responsible for growth and proliferation of activated T cells and expression of autoinflammatory cytokines. This mechanism of action results in immunosuppression and prevents organ rejection.

However, therapeutic drug monitoring is required for tacrolimus since the range between tacrolimus therapeutic and toxic tacrolimus whole blood concentrations is narrow and some toxicities are serious and/or irreversible. The objective of this study is to investigate the bioequivalence of generic Tacrolimus and RLD in healthy male and non-pregnant, non-lactating female volunteers under fasting conditions.

The outcome of this study will help further understanding about pharmacokinetic (PK) performance of tacrolimus in a healthy volunteer population and improve review standards for bioequivalence of narrow therapeutic index (NTI) drugs.

Details
Condition Healthy Volunteers
Treatment Tacrolimus
Clinical Study IdentifierNCT04725682
SponsorFood and Drug Administration (FDA)
Last Modified on24 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 59 yrs?
Gender: Male or Female
Do you have any of these conditions: Do you have Healthy Volunteers??
Males and female volunteers, 18 -59 years of age (inclusive)
BMI that is within 18.5-33.0 kg/m, inclusive
Healthy, according to medical history, ECG, vital signs, laboratory results and physical examination as determined by the PI/Sub-Investigator
Capable of giving written informed consent prior to receiving any study medication
Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements
Smokers: Capable of refraining from smoking for the duration of the confinement
Female subjects must be non-pregnant, non-lactating and fulfill at least one of the
following
Be surgically sterile for a minimum of 6 months
Post-menopausal for a minimum of 12 months; Menopause defined as 12 months of amenorrhea without any other obvious pathological or physiological cause
Agree to avoid pregnancy and use medically acceptable method of contraception from at least 30 days prior to the study until 30 days after the study has ended (last study procedure)
Medically acceptable methods of contraception include non-hormonal
intrauterine device or double barrier method (foam or vaginal spermicidal
suppository in conjunction with a male condom, diaphragm with spermicide in
conjunction with a male condom). Abstinence as a method of contraception is
acceptable if it is in line with the preferred and usual lifestyle of the
study participant
If a female subject becomes pregnant during participation in the study or
within 30 days after she has completed her last tacrolimus administration
(whichever was administered last), she must inform BPSUSA staff immediately
\. Males who are able to father children must agree to use medically
acceptable methods of contraception and not to donate sperm during the study
and for 30 days after the end of the study
Medically acceptable methods of contraception include using a condom with a
female partner of child-bearing potential who is using: oral contraceptives
hormonal patch, implant or injection, intrauterine device, or diaphragm with
spermicide
If a male subject's partner becomes pregnant during his participation in the
study or within 30 days after he has completed his last tacrolimus
administration (whichever was administered last), he must inform BPSUSA staff
immediately

Exclusion Criteria

Known history and/or presence of any clinically significant hepatic (e.g., hepatitis, jaundice, hepatic failure, hepatic necrosis, hepatic encephalopathy, biliary tract diseases, cirrhosis), renal/genitourinary (e.g., urethral stricture, any renal impairment), gastrointestinal, cardiovascular (e.g., hypotension including orthostatic hypotension, cor pulmonale, congenital long QT, congestive heart failure, bradyarrhythmias), cerebrovascular, pulmonary (e.g., chronic obstructive pulmonary disease, decreased respiratory reserve, hypoxia, pre-existing respiratory depression), endocrine (e.g., myxedema, hypothyroidism, adrenal cortical insufficiency), immunological, musculoskeletal (e.g., kyphoscoliosis), neurological (e.g., CNS depression or coma, increased cerebrospinal pressure), psychiatric (e.g., psychosis, depression, hallucinations, delirium tremens, suicidal thoughts or behavior), dermatological or hematological (e.g., thrombocytopenic purpura) disease or condition unless determined as not clinically significant by the PI/Sub- Investigator
History or presence of any clinically significant gastrointestinal pathology (e.g., chronic diarrhea, inflammatory bowel disease), unresolved gastrointestinal symptoms (e.g., diarrhea, vomiting), or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug experienced within 7 days prior to first tacrolimus administration, as determined by the PI/Sub-Investigator
Systolic blood pressure outside 90-130 mmHg, inclusive, and diastolic blood pressure outside 55-80 mmHg, inclusive, and heart rate between 50-100 bpm, inclusive, unless deemed otherwise by the PI/Sub-Investigator
QTc interval 440 milliseconds for males and 460 milliseconds for females, unless deemed otherwise by the PI/Sub-Investigator
Abnormal clinical laboratory values unless values are deemed by the PI/SubInvestigator as "Not Clinically Significant
Abnormal vital signs (blood pressure [BP], heart rate [HR], respiratory rate [RR], pulse oximetry and temperature) measurements, unless deemed otherwise by the PI/Sub-Investigator
Presence of any clinically significant illness within 30 days prior to first dosing, as determined by the PI/Sub-Investigator
Presence of any significant physical or organ abnormality as determined by the PI/Sub-Investigator
A positive test result for any of the following: HIV, Hepatitis B surface antigen, Hepatitis C, drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), and alcohol test. Positive serum or urine pregnancy test for female subjects
Known history or presence of
Alcohol abuse or dependence within one year prior to first study drug administration
Drug abuse or dependence
Hypersensitivity or idiosyncratic reaction to tacrolimus, its excipients, and/or related substances
Lymphoma and other malignancies (particularly of the skin)
Bacterial, viral, fungal and protozoal infections (e.g., polyoma virusassociated nephropathy [PVAN] due to BK virus infection, JC virus associated progressive multifocal leukoencephalopathy [PML], Epstein Barr Virus (EBC) associated Post transplant lymphoproliferative disorder [PTLD], cytomegalovirus (CMV) infections associated CMV viremia and CMV disease)
Tuberculosis
Posterior reversible encephalopathy syndrome (PRES)
Pure red cell aplasia (PRCA)
Gastrointestinal perforation
Hyperkalemia
Hypertension
Lactose intolerance, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
Food allergies and/or presence of any dietary restrictions unless deemed by the PI/Sub-I as "Not Clinically Significant
Severe allergic reactions (e.g. anaphylactic reactions, angioedema)
History of intolerance to and/or difficulty with blood sampling through venipuncture
Abnormal diet patterns (for any reason) during the four weeks preceding the study, including fasting, high protein diets, vegan, etc
Individuals who have donated, in the days prior to first tacrolimus administration
-499 mL of blood in the previous 30 days
mL or more or double red blood cell ("Power red") donation in the previous 56 days
Donation of plasma by plasmapheresis within 7 days prior to first tacrolimus administration
Hemoglobin level of 12.0 g/dL or lower
Individuals who have participated in another clinical trial or who received an investigational drug within 30 days prior to first tacrolimus administration
Not being able to fast for at least 14 hours
Consumption of food or beverages containing grapefruit and/or pomelo within 3 days prior to first study drug administration
Consumption of food or beverages containing caffeine/methylxanthines, poppy seeds and/or alcohol within 48 hours before dosing in each study period
Use of any prescription medication within 14 days prior to first tacrolimus administration (except for allowed contraceptive products)
Use of any over-the-counter medications (including low-dose aspirin, oral multivitamins, allergy medications, herbal and/or dietary supplements) within 14 days prior to first tacrolimus administration (except for spermicidal/barrier contraceptive products)
Use of any enzyme-modifying drugs and/or other products, including inhibitors of cytochrome P450 (CYP) enzymes such as antifungals (e.g., ketoconazole, itraconazole, fluconazole, voriconazole, posaconazole, clotrimazole), macrolide antibiotics (e.g., erythromycin, clarithromycin, josamycin), protease inhibitors (e.g., ritonavir, telaprevir [IncivekTM], boceprevir [VictrelisTM], nelfinavir [Viracept], saquinavir), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), nucleotide reverse transcriptase inhibitors (e.g., tenofovir), gastric acid, suppressors/neturalizers (e.g., lansoprazole, omeprazole, cimetidine, cisapride, magnesium-aluminum hydroxide antacids), bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, midazolam, nilvadipine, quinidine, tamoxifen, and triacetyl- oleandomycin and inducers of CYP enzymes such as anti-myobacterials (e.g., rifampin, rifabutin), antifungal agent (e.g., caspofungin), anticonvulsants (e.g. phenytoin, carbamazepine, phenobarbital), corticosteroids (e.g. prednisolone or methylprednisolone), metamizole, isoniazid and products containing St. John's Wort in the previous 30 days before first study drug administration
Use of medicines such as, mycophenolic acid (MPA) products, aminoglycosides, gyrase inhibitors, vancomycin, cotrimoxazole, NSAIDs, oral anticoagulants, or oral antidiabetics, ganciclovir, acyclovir, amphotericin B, ibuprofen, cisplatin, potassium supplements, potassium- sparing diuretics (e.g., amiloride, triamterene or spironolactone), ACE inhibitors (for example, benazepril, enalapril, quinapril), statins (for example, atorvastatin, fluvastatin, simvastatin), angiotensin receptor blockers (for example, irbesartan, valsartan, azilsartan), nefazodone, metoclopramide, danazol, and herbal products containing Schisandra sphenanthera extracts should be avoided during treatment with tacrolimus in the previous 30 days before first study drug administration
Use of any QT prolonging drugs (e.g., citalopram, chlorpromazine, haloperidol, methadone), amiodarone [CordaroneTM, NexteroneTM, PaceroneTM], immunosuppressive or immunomodulating therapies (e.g. sirolimus [Rapamune], cyclosporins [Gengraf, Neoral, and Sandimune], antilymphocytic antibodies [e.g., basiliximab, daclizumab]) should be avoided during treatment with tacrolimus in the previous 30 days before first study drug administration
Individuals having undergone any major surgery within 6 months prior to the start of the study, unless deemed otherwise by PI/Sub-Investigator
Does not agree, to refrain from driving or operating heavy machinery if feeling dizzy or drowsy following tacrolimus administration until full mental alertness is regained
Does not have an ability to fast for at least 14 hours
Recent history (within 8 weeks prior to screening) of travel to or emigration from any country with high incidence of tuberculosis
Temperature at visit is 100.4 F (38.0C)
Test positive for SARS-CoV-2 by locally available, verified test
Have had common symptoms of COVID-19 currently or in the past 14 days as documented in the COVID-19 screening questionnaire and symptom checklist
Have had an exposure to suspected or confirmed cases of COVID-19 in the past two weeks as documented in the COVID-19 screening questionnaire
Recent live attenuated vaccine1 recipients in the past month
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note